A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Anna FurlanMichele CeaLaura PavanMonica GalliCristina ClissaSilvia MangiacavalliAnna Maria CafroStefania GirlandaFrancesca PatriarcaClaudia MinottoGiovanni BertolderoGregorio BarilàAnna PascarellaAlbana LicoRossella PaoliniNicholas RabassiNorbert PescostaMarika PorrazzoGiovanni De SabbataAlessandra PompaGiulia BegaStefania CavallinFrancesca GuidottiMagda MarcattiMaurizio RupoloAngelo BelottiFilippo GherlinzoniRenato Zambello

Published in: Cancer medicine (2024)

IRd might be effective and safe in RRMM pts with an indolent disease, in early lines of treatment, and who proved Len-sensitive, independent of age, and cytogenetic risk.

Keyphrases

multiple myeloma
hodgkin lymphoma
low dose
acute lymphoblastic leukemia
acute myeloid leukemia
cross sectional
diffuse large b cell lymphoma
combination therapy
newly diagnosed